My response to F1ash. The author forgot to dis

Quote:

---

The author forgot to discuss B-UP (not sure on purpose or not). Here're the results.

https://investorshub.advfn.com/boards/read_ms...=139534431

Oral formulation for CD/UC aside, the foam/gel formulation for UP/UPS is a $1B+ market. Based on the strength of the POC data backed by endoscopic images, the odds of success is high.

Quote:

---

BD therapy generally focuses on anti-inflammatory immunosuppression based on the severity and location of the disease. Rectally-applied treatments can be particularly effective in treating distal colitis -- e.g., suppositories for UP or enema/foam preparations for UPS. Common medications for the treatment of UP/UPS include steroids and 5-aminosalicyclic acid (5-ASA), a $1.4 billion market.

---

http://www.ipharminc.com/new-blog/2017/7/13/u...-to-emerge

As for B-OM, the FDA won't reject drugs just because the second half of data is worse than the first half. Likewise, they won't approve drugs just because the second half of data is better than the first half. They need to look at the complete data. That's why the statistics and CSR is done at the end. The placebo response of 60% was lower than the historical # of 70-75%. Soligenix’s Phase 2 trial had a typical placebo response of 74%.

https://www.sciencedirect.com/science/article...5616315668

Here're the B-OM results. Bottom line, patients in the B-OM arm were 50% less likely to develop SOM than placebo.

---